Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 6/20 | 0.59 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 5/20 | 0.59 |
| ▸ | CA12 | O43570 | 5/20 | 0.59 |
| ▸ | CA9 | Q16790 | 5/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.59 |
| ▸ | CA3 | P07451 | 2/20 | 0.59 |
| ▸ | CA6 | P23280 | 2/20 | 0.59 |
| ▸ | CA5A | P35218 | 2/20 | 0.59 |
| ▸ | CA7 | P43166 | 2/20 | 0.59 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | F2 | P00734 | 2/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7053219 | 1.00 | CA2 (0.59) | CA2CA1CA12CA9CA14 | |
| SCHEMBL40244 | 0.98 | CA2 (0.61) | CA2CA1CA12CA9CA14 | |
| SCHEMBL1729812 | 0.83 | CA1 (0.51) | CA2CA1CA12CA9CA14 | |
| SCHEMBL18547450 | 0.83 | SRD5A2 (0.62) | CA2CA1CA12CA9CA14 | |
| Hydrochloric Acid SCHEMBL1338222 | 0.81 | CA1 (0.64) | CA2CA1CA12CA9CA14 | |
| SCHEMBL7917653 | 0.81 | ALDH1A1 (0.50) | CA2CA1CA12CA9CA14 | |
| SCHEMBL35155 | 0.79 | ALDH1A1 (0.48) | CA2CA1CA12CA9CA14 | |
| Hydrochloric Acid SCHEMBL11747331 | 0.79 | CA2 (0.61) | CA2CA1CA12CA9CA14 | |
| SCHEMBL28554454 | 0.79 | ALDH1A1 (0.48) | CA2CA1CA12CA9CA14 | |
| SCHEMBL9822529 | 0.78 | ALDH1A1 (0.60) | CA2CA1CA12CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3911646-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS | Fondazione Istituto Italiano di Tecnologia (IT) | 2021-11-24 | — | — | EP | disclosed |
| WO-2020148703-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2020-07-23 | — | — | WO | disclosed |
| EP-2590948-A1 | NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS | Wyeth LLC (US) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012004748-A1 | NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS | WYETH LLC (US) | 2012-01-12 | — | — | WO | disclosed |
| US-20120010205-A1 | NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS | WYETH LLC (US) | 2012-01-12 | — | — | US | disclosed |
| US-20050282793-A1 | Steroid prodrugs with androgenic action | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-12-22 | — | — | US | disclosed |
| US-20050277625-A1 | Estriol and estetrol prodrugs | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-12-15 | — | — | US | disclosed |
| US-3931119-A | AROMATIC CARBOXAMIDE-SULPHONAMIDE POLYCONDENSATES | RHONE-POULENC S.A. (FR) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282793-A1 | Steroid prodrugs with androgenic action | CYP21A2, CYP17A1, NR5A1 | CA2 2329/4885DRD1 3000/4885CA1 1614/4885 |
| US-20050277625-A1 | Estriol and estetrol prodrugs | HSD17B11, CYP19A1, ESR1 | CA2 3004/4885DRD1 4065/4885CA1 1643/4885 |
| US-20120010205-A1 | NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS | NR1H2, NR1H3, NR1H4 | CA2 4719/4885DRD1 3024/4885CA1 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.